Stifel Reiterates Buy on Biomarin Pharmaceutical, Maintains $101 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has reiterated a Buy rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $101.
December 21, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Paul Matteis reiterates a Buy rating on Biomarin Pharmaceutical with a maintained price target of $101.
The reiteration of a Buy rating by a Stifel analyst, along with the maintenance of a $101 price target, is a positive endorsement for Biomarin Pharmaceutical. This could lead to increased investor confidence and a potential short-term uplift in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100